Effects of Cytochrome P450 Oxidoreductase Genotypes on the Pharmacokinetics of Amlodipine in Healthy Korean Subjects

Overview

Journal Mol Genet Genomic Med

Specialty Genetics

Date 2020 Mar 6

PMID 32134573

Citations 3

Authors

Ji Min Han

Jeong Yee

Jee Eun Chung

Kyung Eun Lee

Kyungsoo Park

Hye Sun Gwak

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to investigate the effects of P450 oxidoreductase (POR) genetic polymorphisms on the pharmacokinetic parameters of amlodipine.

Methods: After a single 10-mg dose of amlodipine administration, 25 healthy male subjects completed genotyping for 12 single nucleotide polymorphisms (SNPs) of the POR genes, cytochrome P450 (CYP)3A4 g.25343G>A (CYP3A4*1G), and CYP3A5 g.12083G>A (CYP3A5*3). Stratified analysis and in silico analysis to predict the possible effects of given variants on splicing were performed.

Results: The maximum blood concentration (C ) of amlodipine in carriers of g.57332T>C and g.56551G>A SNPs of the POR gene was statistically significantly different. In addition, T-allele carriers of g.57332T>C had a 21% higher C than those with the CC genotype (p = .007). Subjects who carried the wild-type g.56551G>A allele also had a 1.12-fold significantly higher C than subjects with mutant-type homozygous carriers (p = .033). In stratified analyses, g.57332T>C was significantly associated with a 1.3-fold increase in C value in T-allele carriers compared with subjects with the CC genotype in CYP3A4 and CYP3A5 expressers. POR g.57332T>C increased the score above the threshold in both ESEfinder 3.0 and HSF 3.1.

Conclusion: This study identified a novel SNP of the POR gene, which affected amlodipine metabolism and may reduce interindividual variation in responses to amlodipine.

Citing Articles

A Multivariate prediction model for amlodipine therapeutic efficacy in pediatric primary hypertension.

Lin Y, Wang H, Li Y, Liu Y, Liu Y, Zhang H Front Endocrinol (Lausanne). 2025; 16:1542276.

PMID: 40007810 PMC: 11850241. DOI: 10.3389/fendo.2025.1542276.

Genetic Variation in and Affects Amlodipine Pharmacokinetics and Safety.

Soria-Chacartegui P, Zubiaur P, Ochoa D, Villapalos-Garcia G, Roman M, Matas M Pharmaceutics. 2023; 15(2).

PMID: 36839726 PMC: 9959242. DOI: 10.3390/pharmaceutics15020404.

Evaluation for Potential Drug-Drug Interaction of MT921 Using In Vitro Studies and Physiologically-Based Pharmacokinetic Models.

Ryu H, Moon H, Lee J, Yang G, Yang S, Yun H Pharmaceuticals (Basel). 2021; 14(7).

PMID: 34358080 PMC: 8308925. DOI: 10.3390/ph14070654.

Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects.

Han J, Yee J, Chung J, Lee K, Park K, Gwak H Mol Genet Genomic Med. 2020; 8(5):e1201.

PMID: 32134573 PMC: 7216797. DOI: 10.1002/mgg3.1201.

References

Ozdemir V, KALOW W, Tang B, Paterson A, Walker S, Endrenyi L . Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000; 10(5):373-88. DOI: 10.1097/00008571-200007000-00001. View

Zhu Y, Wang F, Li Q, Zhu M, Du A, Tang W . Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2013; 42(2):245-9. DOI: 10.1124/dmd.113.055400. View

Yuan R, Zhang X, Deng Q, Wu Y, Xiang G . Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Clin Chim Acta. 2011; 412(9-10):755-60. DOI: 10.1016/j.cca.2010.12.038. View

Kim K, Park P, Lee O, Kang D, Park J . Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol. 2006; 47(1):87-93. DOI: 10.1177/0091270006295063. View

Lee J, van Heeswijk R, Alves K, Smith F, Garg V . Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother. 2011; 55(10):4569-74. PMC: 3187007. DOI: 10.1128/AAC.00653-11. View

Gabriel S, Schaffner S, Nguyen H, Moore J, Roy J, Blumenstiel B . The structure of haplotype blocks in the human genome. Science. 2002; 296(5576):2225-9. DOI: 10.1126/science.1069424. View

Agrawal V, Choi J, Giacomini K, Miller W . Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet Genomics. 2010; 20(10):611-8. PMC: 2940949. DOI: 10.1097/FPC.0b013e32833e0cb5. View

Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J . Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001; 27(4):383-91. DOI: 10.1038/86882. View

MEREDITH P, Elliott H . Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992; 22(1):22-31. DOI: 10.2165/00003088-199222010-00003. View

10.

Park J, Kim K, Park P, Lee O, Kang D, Shon J . Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther. 2006; 79(6):590-9. DOI: 10.1016/j.clpt.2006.02.008. View

11.

Ma Y, Xin S, Huang M, Yang Y, Zhu C, Zhao H . Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters. Pharmacogenomics J. 2016; 17(4):325-330. DOI: 10.1038/tpj.2016.31. View

12.

Park P, Seo Y, Ahn J, Kim K, Park J . Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J Clin Pharm Ther. 2009; 34(5):569-74. DOI: 10.1111/j.1365-2710.2009.01057.x. View

13.

Westlind A, Malmebo S, Johansson I, Otter C, Andersson T, Ingelman-Sundberg M . Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun. 2001; 281(5):1349-55. DOI: 10.1006/bbrc.2001.4505. View

14.

Nelson D, Koymans L, Kamataki T, Stegeman J, Feyereisen R, Waxman D . P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996; 6(1):1-42. DOI: 10.1097/00008571-199602000-00002. View

15.

Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T . Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat. 2003; 23(1):100. DOI: 10.1002/humu.9210. View

16.

Kim Y, Son M, Lee D, Roh H, Son H, Chae D . Pharmacokinetic comparison of 2 fixed-dose combination tablets of amlodipine and valsartan in healthy male Korean volunteers: a randomized, open-label, 2-period, single-dose, crossover study. Clin Ther. 2013; 35(7):934-40. DOI: 10.1016/j.clinthera.2013.05.021. View

17.

Huang N, Agrawal V, Giacomini K, Miller W . Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A. 2008; 105(5):1733-8. PMC: 2234213. DOI: 10.1073/pnas.0711621105. View

18.

Raponi M, Baralle D . Alternative splicing: good and bad effects of translationally silent substitutions. FEBS J. 2010; 277(4):836-40. DOI: 10.1111/j.1742-4658.2009.07519.x. View

19.

Zhou Q, Yu X, Shu C, Cai Y, Gong W, Wang X . Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J Hum Genet. 2011; 56(6):415-22. DOI: 10.1038/jhg.2011.30. View

20.

Pagani F, Baralle F . Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet. 2004; 5(5):389-96. DOI: 10.1038/nrg1327. View